US Top Rating Updates on 11/1: EMR, UNP, FSLR, REGN and More

Barclays analyst Christine Cho upgraded $First Solar (FSLR.US)$ to Equal Weight from Underweight with a price target of $162, up from $89. Demand for domestically-manufactured products support First Solar's pricing power while its almost sold-out status through 2026 "kicks the concern about potential ASP deterioration down the road," Cho tells investors in a research note.

RBC Capital analyst Walter Spracklin upgraded $Norfolk Southern (NSC.US)$ to Sector Perform from Underperform with a price target of $237, up from $221, following its Q3 earnings beat. The analyst cites the company's solid operating trends relative to expectations exiting Q3.

EF Hutton analyst Michael King initiated coverage of $Regeneron Pharmaceuticals (REGN.US)$ with a Buy rating and $851 price target. The analyst says Regeneron embodies the best elements of a "classic" biotechnology company while having the "scientific and financial wherewithal to catapult itself into the upper echelon of market capitalization of the mega-cap biotech sector and, eventually, the global pharmaceutical sector."